StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report issued on Friday. The brokerage issued a sell rating on the stock.
OncoCyte Price Performance
Shares of NASDAQ OCX opened at $2.53 on Friday. The business has a 50 day simple moving average of $2.96 and a 200 day simple moving average of $3.06. OncoCyte has a 52 week low of $2.08 and a 52 week high of $6.80.
Insider Activity at OncoCyte
In other news, Director Andrew Arno purchased 33,898 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Andrew Arno bought 33,898 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The disclosure for this purchase can be found here. In the last quarter, insiders bought 2,457,288 shares of company stock valued at $7,176,400. 1.94% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On OncoCyte
OncoCyte Company Profile
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Further Reading
- Five stocks we like better than OncoCyte
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- The Charles Schwab Company Can Hit New Highs
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Investing in Construction Stocks
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.